1. Switzerland Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
BB Biotech AG

BB Biotech AG

49.85
CHF
-0.55
(-1.09%)
14.55EPS
3.32P/E
2.66BMarket Cap
Oct 23Next Earn
BB Biotech AG
IOB:0JYO
(London Stock Exchange (International))

Recent

price

49.85

P/E

ratio

3.32

div

yld

4.52%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
-8.96
-4.08
32.16
82.3
130.35
11.8
-14.41
12.52
-8.41
12.37
12.62
-7.16
-6.38
-3.64
1.5
10.7
15
Revenue per Share
-9.27
-4.55
31.39
81.77
129.8
11.69
-14.51
12.42
-8.51
12.23
12.48
-7.31
-6.5
-3.77
1.38
10.54
14.55
Basic EPS, GAAP
-1.48
11.84
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
3.76
3.3
- -
4.48
7.01
2.33
2.9
2.75
3.3
3.05
3.4
3.6
3.86
2.85
2
1.8
2.25
Dividend per Share
81.03
76.09
108.64
31.05
61.91
71.43
54.22
63.88
52.07
61.25
70.17
59.38
48.98
42.36
41.75
50.39
55.93
Book Value per Share
81.03
76.09
108.64
31.05
61.91
71.43
54.22
63.88
52.07
61.25
70.17
59.38
48.98
42.36
41.75
50.39
55.93
Tangible Book Value per Share
16
14
12
11
11
56
55
55
55
55
55
55
55
55
55
55
55
Basic Weighted Avg Shares
-142
-58
377
938
1,476
659
-796
693
-466
685
699
-396
-351
-200
82
587
826
Sales/Revenue/Turnover
103.34
111.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-146
-65
368
932
1,470
653
-802
688
-471
677
691
-405
-358
-207
76
578
801
Net Income, GAAP
- -
- -
0.08
0.01
0.01
0.01
- -
0.01
- -
0.01
0.01
- -
- -
- -
0.07
0.01
0.01
Effective Tax Rate (%)
103.4
111.64
97.62
99.35
99.58
99.03
100.71
99.2
101.2
98.86
98.85
102.17
101.87
103.53
92.2
98.49
97.04
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
140
145
135
90
30
160
205
95
185
150
63
355
363
305
118
- -
- -
LT Debt
1,235
1,002
1,234
2,119
3,493
3,978
3,003
3,539
2,885
3,393
3,888
3,283
2,686
2,323
2,286
2,779
3,084
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
29.24
52.09
51.3
17.04
- -
20.1
- -
20.49
18.45
- -
- -
- -
3.02
22.31
31.86
Return on Capital (%)
-10.64
-5.82
32.91
55.58
52.4
17.48
-22.98
21.02
-14.68
21.58
18.99
-11.29
-11.99
-8.25
3.29
22.83
31.86
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
55
55
55
Market Capitalization
2,490
2,367
2,664

Working Capital

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
98
355
204
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.02%
-5.46%
21.54%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-50.63%
62.51%
661.71%
Sales/Revenue/Turnover
-55.95%
52.13%
613.11%
Total Cash Common Dividend
-1.18%
-10.82%
-10.21%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
262
-79
-150
61
82
2025
-239
-94
- -
475
587
2026
-17
462
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4.75
-1.6
-2.87
1.09
1.38
2025
-4.4
-1.83
- -
8.55
10.54
2026
-0.39
8.18
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
- -
- -
- -
2
2025
1.8
- -
- -
- -
1.8
2026
2.25
- -
- -
- -
- -
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
BB Biotech AG BB Biotech AG is a Swiss investment company that invests in publicly listed biotechnology firms developing and commercializing innovative drugs and therapies addressing unmet medical needs in oncology, neurological disorders, metabolic and cardiovascular diseases, infectious diseases, and autoimmune conditions; its portfolio, comprising 20 to 35 companies primarily in the United States and Western Europe, includes key holdings such as Argenx SE, Incyte, Relay Therapeutics, MacroGenics, Scholar Rock, Rivus Pharmaceuticals, Edgewise Therapeutics, Immunocore, Biohaven, and Avidity Biosciences, among others focused on cell, gene, and RNA-based technologies. Founded in 1993 and headquartered in Schaffhausen, Switzerland, BB Biotech AG operates globally with a focus on small- to mid-cap biotech entities aligned with the UN Sustainable Development Goal for good health and well-being, and its shares trade on the SIX Swiss Exchange and Frankfurt Stock Exchange. Recent developments include four major portfolio company acquisitions in 2025—Avidity Biosciences by Novartis for USD 12 billion, Intra-Cellular Therapies by Johnson & Johnson for USD 14.6 billion, Blueprint Medicines by Sanofi for up to USD 9.5 billion, and Akero Therapeutics by Novo Nordisk for up to USD 5.2 billion—alongside a new investment in Avidity Biosciences, portfolio reallocation toward high-potential assets like Ionis Pharmaceuticals and Alnylam Pharmaceuticals, and inclusion in the SPI ESG Index.